

In the Claims:

Please cancel claims 47-70 and 73-95 without prejudice.

Please amend the claims to read as follows:

1-70. (Canceled)

71. (Currently Amended) A process for treating a transplant recipient ~~for graft versus-host disease~~ to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising

~~treating the recipient of a donor transplant with~~ administering to a transplant recipient mesenchymal stem cells in an amount effective to reduce an immune response ~~against the recipient by the transplant~~ of effector cells against a xenoantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the xenoantigen.

72. (Previously Added) A process for reducing an immune response against an alloantigen, comprising contacting immune effector cells with at least one member selected from the group consisting of xenogeneic mesenchymal stem cells and a supernatant of xenogeneic mesenchymal stem cells in an amount effective to reduce the immune response.

73-95. (Canceled)

96. (New) The process of claim 71 wherein said effector cells are T cells.

97. (New) The process of claim 96 wherein the T cells are from the donor and the xenoantigen is from the recipient.

98. (New) The process of claim 71 wherein the T cells are from the recipient and the xenoantigen is from the donor.

99. (New) The process of claim 71 wherein said T cells are present in a transplant.

101. (New) The process of claim 71 wherein said MSCs are administered to a transplant recipient suffering from graft-versus-host disease.

102. (New) The process of claim 71 wherein prior to said administration said mesenchymal stem cells (MSCs) have been expanded in culture.

103. (New) The process of claim 71 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.

104. (New) The process of claim 71 wherein the transplant is skin.

105. (New) The process of claim 71 wherein the mesenchymal stem cells are administered to the transplant recipient to treat rejection of the transplant by the recipient.

106. (New) The process of claim 71 wherein the mesenchymal stem cells are human mesenchymal stem cells.

107. (New) The process of claim 71 further comprising administering to the recipient immunosuppressive agents.

108. (New) The process of claim 71 wherein the transplant is a solid organ.

109. (New) The process of claim 108 wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.

110. (New) The process of claim 71 wherein said mesenchymal stem cells are administered prior to said transplant.

111. (New) The process of claim 71 wherein said mesenchymal stem cells are administered concurrently with said transplant.

112. (New) The process of claim 71 wherein said mesenchymal stem cells are administered as part of the transplant.

113. (New) The process of claim 71 wherein the mesenchymal stem cells are administered subsequent to transplant.

114. (New) The process of claim 71 wherein said mesenchymal stem cells are administered intravenously to the recipient.

115. (New) The process of claim 71 wherein said effector cells are cells of a recipient of said donor transplant.

116. (New) A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising:

transplanting to a transplant recipient a transplant treated with mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the xenoantigen.

117. (New) The process of claim 116 wherein said effector cells are T cells.